Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Fluvoxamine for Outpatient COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-Analysis

View ORCID ProfileTodd C. Lee, View ORCID ProfileSimone Vigod, Émilie Bortolussi-Courval, View ORCID ProfileRyan Hanula, View ORCID ProfileDavid R. Boulware, View ORCID ProfileEric J. Lenze, View ORCID ProfileAngela M. Reiersen, View ORCID ProfileEmily G. McDonald
doi: https://doi.org/10.1101/2021.12.17.21268008
Todd C. Lee
1Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montréal, Canada
2Clinical Practice Assessment Unit, Department of Medicine, McGill University Health Centre, Montréal, Canada
3Division of Experimental Medicine, Department of Medicine, McGill University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Todd C. Lee
  • For correspondence: todd.lee@mcgill.ca
Simone Vigod
4Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto and Women’s College Hospital, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Simone Vigod
Émilie Bortolussi-Courval
3Division of Experimental Medicine, Department of Medicine, McGill University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryan Hanula
3Division of Experimental Medicine, Department of Medicine, McGill University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ryan Hanula
David R. Boulware
5Division of Infectious Diseases & International Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David R. Boulware
Eric J. Lenze
6Department of Psychiatry, School of Medicine, Washington University in Saint Louis, St. Louis, Missouri, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eric J. Lenze
Angela M. Reiersen
6Department of Psychiatry, School of Medicine, Washington University in Saint Louis, St. Louis, Missouri, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Angela M. Reiersen
Emily G. McDonald
2Clinical Practice Assessment Unit, Department of Medicine, McGill University Health Centre, Montréal, Canada
3Division of Experimental Medicine, Department of Medicine, McGill University
7Division of General Internal Medicine, Department of Medicine, McGill University Health Centre, Montréal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Emily G. McDonald
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Importance Widely available and affordable options for the outpatient management of COVID-19 are needed, particularly therapies that prevent hospitalization.

Objective Perform a meta-analysis of the available randomized clinical trial evidence for fluvoxamine in the outpatient management of COVID-19.

Data Sources World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov.

Study Selection Completed outpatient trials with available results which compared fluvoxamine to placebo.

Data Extraction and Synthesis We followed the PRISMA 2020 guidelines. We extracted study details in terms of inclusion criteria, trial demographics and the pre-specified outcome of all-cause hospitalization. Risk of bias was assessed by the Cochrane Risk of Bias 2 tool. We conducted a frequentist random effects meta-analysis, as well as two sensitivity analyses using a Bayesian random effects meta-analysis with different estimates of prior probability: a weakly neutral prior (50% chance of efficacy with 95% confidence interval for Risk Ratio [RR] between 0.5 and 2) and a moderately optimistic prior (85% chance of efficacy). We contextualized the results by estimating the probability of any effect (RR ≤1) and moderate effect (RR ≤0.9) on reducing hospitalization.

Main Outcome(s) and Measure(s) All cause hospitalization.

Results 2196 participants were included from 3 identified trials. The risk ratios for hospitalization were 0.75 (95%CI, 0.57-0.97) for the frequentist analysis, 0.78 (95%CI 0.58-1.08) for the Bayesian weakly neutral prior, and 0.73 (95%CI, 0.53-1.01) for the Bayesian moderately optimistic prior. Depending on the scenario, the probability of any effect on hospitalization ranged from 94.1% to 98.3% and a moderate effect from 81.6% to 91.1%.

Conclusions and Relevance Under a variety of assumptions, fluvoxamine shows a high probability of preventing hospitalization in outpatients with COVID-19. While ongoing randomized trials are important to evaluate alternative doses, explore the effectiveness in vaccinated patients, and provide further refinement to these estimates, fluvoxamine could be recommended as a treatment option, particularly in resource-limited settings or persons without access to SARS-CoV-2 monoclonal antibody therapy or direct antivirals.

Question Does early administration of fluvoxamine prevent hospitalization in symptomatic adult outpatients with confirmed COVID-19?

Findings In this meta-analysis with Bayesian sensitivity analyses that accounted for varying prior probabilities, there was a high probability (94.1% to 98.3%) that fluvoxamine reduces hospitalization with frequentist risk ratio of 0.75 (95%CI 0.57-0.97).

Meaning Fluvoxamine is a widely available and inexpensive option that prevents hospitalization in patients with early COVID-19 based on randomized controlled trial evidence to date.

Competing Interest Statement

AMR and EJL are co-inventors on a patent application filed by Washington University for methods of treating COVID-19.

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted December 21, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Fluvoxamine for Outpatient COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-Analysis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Fluvoxamine for Outpatient COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-Analysis
Todd C. Lee, Simone Vigod, Émilie Bortolussi-Courval, Ryan Hanula, David R. Boulware, Eric J. Lenze, Angela M. Reiersen, Emily G. McDonald
medRxiv 2021.12.17.21268008; doi: https://doi.org/10.1101/2021.12.17.21268008
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Fluvoxamine for Outpatient COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-Analysis
Todd C. Lee, Simone Vigod, Émilie Bortolussi-Courval, Ryan Hanula, David R. Boulware, Eric J. Lenze, Angela M. Reiersen, Emily G. McDonald
medRxiv 2021.12.17.21268008; doi: https://doi.org/10.1101/2021.12.17.21268008

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (241)
  • Allergy and Immunology (521)
  • Anesthesia (125)
  • Cardiovascular Medicine (1426)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (292)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (586)
  • Epidemiology (10307)
  • Forensic Medicine (6)
  • Gastroenterology (528)
  • Genetic and Genomic Medicine (2637)
  • Geriatric Medicine (254)
  • Health Economics (497)
  • Health Informatics (1740)
  • Health Policy (790)
  • Health Systems and Quality Improvement (676)
  • Hematology (268)
  • HIV/AIDS (568)
  • Infectious Diseases (except HIV/AIDS) (12103)
  • Intensive Care and Critical Care Medicine (649)
  • Medical Education (273)
  • Medical Ethics (83)
  • Nephrology (291)
  • Neurology (2466)
  • Nursing (145)
  • Nutrition (379)
  • Obstetrics and Gynecology (493)
  • Occupational and Environmental Health (568)
  • Oncology (1327)
  • Ophthalmology (403)
  • Orthopedics (147)
  • Otolaryngology (238)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (343)
  • Pediatrics (784)
  • Pharmacology and Therapeutics (330)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2405)
  • Public and Global Health (5019)
  • Radiology and Imaging (895)
  • Rehabilitation Medicine and Physical Therapy (530)
  • Respiratory Medicine (682)
  • Rheumatology (309)
  • Sexual and Reproductive Health (256)
  • Sports Medicine (246)
  • Surgery (298)
  • Toxicology (45)
  • Transplantation (141)
  • Urology (108)